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Background: GASP-2 is a secreted multi-domain glycoprotein known as a speciﬁc inhibitor of myostatin
and GDF-11. Here we investigate the role of GASP-2 on myogenesis and the effect of its glycosylation on
its activity.
Methods: GASP-2 overexpression or knockdown by shRNAs were carried out on C2C12 myoblasts cells. In
silico analysis of GASP-2 protein was performed to identify its glycosylation sites. We produced a mouse
recombinant GASP-2 protein in a prokaryotic system to obtain a fully deglycosylated protein allowing us
to study the importance of this post-translational modiﬁcation on GASP-2 activity.
Results: Both mature and deglycosylated GASP-2 proteins increase C2C12 proliferation and differentia-
tion by inhibiting the myostatin pathway. In silico and western-blot analyses revealed that GASP-2
presents one consensus sequence for N-glycosylation and six potential sites of mucin-type O-glycosy-
lation.
Conclusions: GASP-2 promotes myogenesis and thus independently of its glycosylation.
General signiﬁcance: This is the ﬁrst report demonstrating that GASP-2 promotes proliferation and dif-
ferentiation of myoblasts by inhibiting the canonical pathway of myostatin.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
GASPs (Growth and Differentiation Factor Associated Serum
Protein) are secreted glycoproteins known to interact with myos-
tatin (MSTN), a key regulator of muscle development [1,2]. These
proteins contain multiple protease inhibitors domains [3,4]. Thus,
the two members, GASP-1 and GASP-2 (also named WFIKKN2 and
WFIKKN1) are made of four serine proteases inhibitor modules
(WAP, Follistatin/Kazal and two Kunitz), a Netrin domain which is
implicated in inhibition of metalloproteinases and an Ig domain
involved in protein folding (Igc2) [3,4]. These domains are highly
conserved among mammals especially the Follistatin/Kazal, the
second Kunitz and the Netrin domains [5]. This conservation
strongly suggests the importance of their functions [5]. Since 2003B.V. This is an open access article u
R 1061, Unité de Génétique




esearch, Ottawa Health Re-and its discovery [6], most of the studies have focused on the role
of GASP-1 as a myostatin antagonist. It was shown that GASP-1
interacts with and inhibits myostatin via its Follistatin domain [6–
9]. The myostatin is a member of TGFβ superfamily that negatively
regulates myogenesis mainly via the SMAD2/3 pathway [10]. The
disruption of the MSTN gene in mice leads to a dramatic increase
of skeletal muscle mass due to both hyperplasia and hypertrophy
[1]. Overexpression of myostatin inhibitors, like Follistatin and
FSTL3, leads to an increase of myoblasts proliferation and differ-
entiation and an increase of muscle mass in mice [11,12]. Recently,
we also described in mice overexpressing Gasp-1 a hypermuscular
phenotype owing only to hypertrophy, without hyperplasia of the
myoﬁbers [13]. We demonstrated that in addition to the inhibition
of its canonical pathway, myostatin is up-regulated in these mice
leading to the absence of hyperplasia [14].
Unlike GASP-1, GASP-2 was never found associated with
myostatin in serum although their interaction is well known [8].
As GASP-1 and GASP-2 share 54% of identity and are expressed, at
few exceptions, in similar tissues including skeletal muscle [4], we
asked if GASP-2 could also be involved in the regulation of
myostatin during myogenesis. In this paper, we analyzed at cel-
lular and molecular levels the consequences on myoblasts pro-
liferation and differentiation of Gasp-2 over or knockdown genender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In addition to play a central role on the solubility and half-life of
the protein, glycosylation is well known to modulate its function.
We also analyzed the involvement of this post-translational
modiﬁcation on GASP-2 activity, focusing our study on its role as
an inhibitor of myostatin.2. Materials and methods
2.1. Cell culture
Mouse C2C12 myoblasts [15] were obtained from American
Type Culture Collection (ATCC). C2C12 myoblasts were grown in
Growth Medium (GM) consisting in Dulbecco's Modiﬁed Eagle
Medium (DMEM; Invitrogen) supplemented with 10% Fetal Bovine
Serum (FBS, Invitrogen), 100 units ml1 penicillin and 100 μ
g ml1 streptomycin (Invitrogen). C2C12 differentiation was in-
duced upon 70% conﬂuence by serum withdrawal (DMEM with 2%
horse serum (HS, Invitrogen)). For proliferation assay, C2C12 were
grown or not with 1 μg ml1 of hGASP-2 or mGASP-2 deglycosy-
lated (deglyco-mGASP-2).
2.2. Bioinformatics analyses
GASP-2 orthologs were retrieved from databases using BLAST
(http://www.ncbi.nlm.nih.gov/BLAST) and Ensembl Genome
Browser (www.ensembl.org). Alignment was performed using
ClustalW program and analyzed with WebLogo. Asparagine and
serine/threonine residues potentially glycosylated were identiﬁed
using respectively NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/
services/NetNGlyc/) and NetOGlyc 3.1 Server [16].
2.3. Transient transfections of C2C12 cells
Mouse C2C12 myoblasts at 70% conﬂuence were transiently
transfected using the XtremeGENE 9 Transfection Reagent (Roche
Applied Science) with 5 μg of pcDNA3.1-Gasp-2 or pcDNA3.1-
empty in DMEM serum-free media. After 16 h of transfection, the
medium was replaced and myoblasts were allowed to proliferate
and differentiate for further analyses.
2.4. Production and puriﬁcation of murine GASP-2 in prokaryotic
system
The mouse Gasp-2cDNA coding sequence without peptide sig-
nal were ampliﬁed and cloned into the pGEX-4-T1 plasmid (Sigma
Aldrich). Production was carried out in E.coli BL21 (DE3) in LB
(Luria Bertani) supplemented with 0.2% glucose and 100 μg ml1
ampicillin. Bacteria were grown to reach OD600 at 0.5 and then
induced with 0.025 mM IPTG at 20 °C for 14 h at 250 rpm. Bac-
terial growth was stopped by centrifugation (6000 g, 15 min; 4 °C).
Bacteria were lysed in 20 ml of lysis buffer (20 mM Tris–HCl,
pH7.5, 250 mM NaCl, 1 mM EDTA, 0.05% Triton X-100, 10 mg ml1
lysozyme) and centrifuged (48,000g, 20 min, 4 °C). Puriﬁcation
was carried out with the ÄKTAprime system (Amersham-Bios-
ciences). Supernatant was loaded into a GST-Trap HP 5 ml column
(GE Healthcare) equilibrated in 20 mM sodium phosphate, pH7.3,
0.15 M NaCl. Elution was performed at a rate of 1 ml min1 with
50 mM Tris–HCl, pH8, 10 mM reduced glutathione. Cleavage of the
GST Tag located at the N-terminal region of the fusion protein was
performed with 10 units mg1 of recombinant thrombin protein
(Sigma T68884) by incubation for 16 h at 4 °C. The sample was
then concentrated on an Amicon Ultra 30 K ﬁlter (Millipore) by
centrifugation (4000g, 4 °C).2.5. Quantitative real-time PCR (qPCR)
Total RNA from cells and tissues was isolated using RNeasy midi
kit (Qiagen). Synthesis of cDNA was performed with the High
Capacity cDNA Archive Kit (Applied Biosystems) to convert 2 μg of
total RNA into single-stranded cDNA. Real-time PCR was per-
formed in triplicate using 50 ng of cDNA. Relative amounts of
transcripts were determined using Taqman probes speciﬁc for
Gasp-2 (Mm01308311_m1), β2m (Mm00437762_m1), Dffa
(Mm00507317) and MyoG (Mm00446194_m1), on an ABI PRISM©
7900 System. Relative mRNA expression values were calculated by
the ΔΔCt method with normalization of each sample to the
average change in cycle threshold (Ct) value of the controls. For all
analyses, three independent experiments have been performed,
each assay corresponding to 3 wells /condition/ probe.
2.6. Proliferation assay
Three independent experiments have been carried out. Each
experiment corresponds to the analysis of 12 wells with 2000
cells/well at t¼0 h. The CellTiter 96s AQueous One Solution Cell
Proliferation Assay (Promega) was used to evaluate the cell pro-
liferation during 72 h. 20 ml de MTS solution was added to the cells
for 3 h and absorbance at 490 nm was then recorded with a 96-
well plate reader.
2.7. Fusion index
The fusion index corresponds to the proportion of nuclei pre-
sent within myotubes that contain two or more nuclei. Cells were
washed with phosphate-buffered saline (PBS) and ﬁxed with 4%
paraformaldehyde (PFA) in PBS for 15 min. The fusion index was
analyzed after hematoxylin and eosin (H&E) staining.
2.8. Lentiviral-mediated knockdown of Gasp‐2
Individual shRNA constructs speciﬁcally designed to target the
Gasp-2 were purchased from Sigma Aldrich (Gasp-2_sh1:
XM_128578.3-784s1c1; Gasp-2_sh2: XM_128578.3-500s1c1).
Lentiviral particles, consisting of the shRNA transfer vector PLKO.1-
puro (which contains the sequence of shRNA as well as the cis
acting sequences necessary for RNA production and packaging)
and the mission lentiviral packaging (Sigma Aldrich). Mission
lentiviral particles were generated from different components. The
packaging vector contains the minimal set of lentiviral genes re-
quired to generate the virion structural proteins and packaging
functions. The pCMV-VSV-G envelope vector provides the envel-
ope vector for pseudo-typing. The PLKO.1-puro Gasp-2 shRNA or
empty pLKO.1 and pCMV-VSVG vectors were transfected into
HEK293Tcells using a Lipofectamine 2000 reagent (Invitrogen)
following the manufacturer’s instructions. Brieﬂy, HEK293T cells
were grown in GM at 70-80% conﬂuence and were transfected
with 1 mg of plasmid PLKO.1-puro with the mission lentiviral
packaging mix. After 16 h of transfection, the medium was re-
placed with fresh GM and cells were incubated for a further 60 h.
The supernatant was then collected as a source of viral particles.
C2C12 myoblasts were infected with lentivirus-containing media
for 24 h and selected with 2 μg ml1 puromycin.
2.9. SDS-page and western blot analyses
Cells and tissues were collected in lysis buffer (50 mM Tris,
pH8, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate,
and protease inhibitors) followed by centrifugation at 12,000 g,
20 min, 4 °C. Protein quantiﬁcation was performed with a Bradford
assay. Proteins were separated under denaturing conditions into a
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at 40 mA to a nitrocellulose membrane. Membranes were blocked
in TBS (Tris-Buffered Saline) with 0.1% Tween 20% and 5% non-fat
dry milk. Membranes were incubated overnight with a mono-
clonal mouse CDK2 (1:500, sc-6248, Santa Cruz), a mouse mono-
clonal p21 (1:400, sc-53870, Santa Cruz), a goat polyclonal
SMAD2/3 (1:2000, AF3797, R&D Systems), a polyclonal rabbit
phospho–SMAD3 (1:500, AB3226, R&D Systems), a polyclonal goat
GASP-2 (1:1000, AF2136, R&D Systems), a polyclonal mouse MyHC
(Myosin Heavy Chain, 1:4000, M4276, Sigma Aldrich) and poly-
clonal goat anti-mouse GAPDH antibody, (1:2000, AF5718, R&D
Systems) diluted in 2% non-fat dry milk. After 4 washes in TBS-
Tween 0.1% (v/v), membranes were incubated for 1 h at room
temperature with 1:1000 dilution of secondary antibodies: anti-
goat IgG horse-radish peroxidase (HRP) conjugate (P0449, Dako),
anti-mouse IgG HRP conjugate (P0447, Dako) or anti-rabbit IgG
HRP conjugate (P0399, Dako). After 4 more washes in TBS-Tween
0.1% (v/v), immunoblots were developed by enhanced chemilu-
minescence. The ﬁlms were analyzed using ImageQuant TL soft-
ware (GE Healthcare).
2.10. Glycosylation analysis
N-deglycosylation: 250 ng of puriﬁed proteins were denatured
at 95 °C for 10 min in 10 mM potassium phosphate and 0.2% SDS.
The samples were then incubated overnight at 37 °C in a buffer
(10 mM potassium phosphate, pH8, 10 mM EDTA, 0.5% Triton
X-100, 0.2% SDS, 1% β-mercaptoethanol) containing 0.1–1 U of
PNGase F (Roche Applied Science).
O-deglycosylation: The O-deglycosylation was performed with
the EDEGLY kit (Sigma-Aldrich).
250 ng of puriﬁed proteins were denatured at 100 °C for 5 min
in 2.5 μl of denaturation solution (Sigma-Aldrich) and 10 μl of
reaction buffer 5X. Samples were incubated overnight at 37 °C
with 1 μl of each enzyme (PNGase F, O-Glycosidase, α-(2-
3,6,8,9)-Neuraminidase, β-N-Acetylglucosaminidase, β-(1-4)-
Galactosidase).3. Results
3.1. GASP-2 regulates myogenesis
To study the role of GASP-2 in myogenesis, we treated C2C12
myoblasts cells with 1 mg ml1 of hGASP-2 protein. Cell pro-
liferation assay showed that hGASP-2 treatment improves sig-
niﬁcatively myoblast proliferation rate compared to control cells
(29% at 48 h; 46% at 72 h) (Fig. 1A). We also analyzed the ex-
pression of cyclin-dependent kinase 2 (CDK2) that positively reg-
ulates cell-cycle progression. Western blot analyses showed an
increase of CDK2 in C2C12 myoblasts treated with hGASP-2 com-
pared to the control, consistent with an increased proliferation
rate, while p21 expression, a cyclin-dependent kinase inhibitor
(CKI), decreases in treated myoblasts (Fig. 1B–D). These results
revealed that hGASP-2 treatment promotes cell-cycle progression.
To determine whether the increase of C2C12 proliferation rate in
presence of hGASP-2 was due to an inhibition of myostatin
(MSTN), we evaluated the phospho-SMAD3 (pSMAD3) levels of
C2C12 cells treated with MSTN and/or hGASP-2 (Fig. 1E–F). As
expected C2C12 myoblasts treatment with MSTN leads to an in-
crease of the pSMAD3 rate compared to the untreated myoblasts.
However, hGASP-2 treatment decreases the pSMAD3 signal con-
ﬁrming that hGASP-2 inhibits the MSTN pathway. No change was
shown in the total SMAD2/3 rates (Fig. 1E).
Then, we analyzed the effect of Gasp-2 during C2C12 myoblast
differentiation. We transiently transfected the C2C12 cells with avector containing the Gasp-2 cDNA sequence. Myoblast differ-
entiation was assessed with two clones, Cl1 and Cl2 that over-
express Gasp-2 about 250 times and 80 times respectively
(Fig. 2A). Cl2 presents an increase of 15% of myotube formation in
72 h and 17% at 96 h (Fig. 2B). Fusion index is also signiﬁcantly
increased in Cl1 at 96 h compared to C2C12 and control cells
(Fig. 2B). No variation in myotubes size was observed in both
clones. Consistent with the increase of C2C12 differentiation,
myogenin expression, a Myogenic Regulatory Factor (MRF) re-
quired for myoblast differentiation, was up-regulated 10 times at
24 h and 48 h of differentiation in the Cl2 myotubes when com-
pared to the control cells (Fig. 2C). Myogenin expression was also
slightly up-regulated in Cl1 compared to control cells (Fig. 2C).
Differences in transcript levels of Gasp-2 in both clones (Fig. 2A)
and the observed Gasp-2 overexpression effect on differentiation
(Fig. 2B and C) suggests that there is no dose-dependent con-
sequence on cell differentiation.
In addition, we generated cell lines that underexpress Gasp-2
using two different lentivirus based-shRNA. These cell lines were
named KD1 and KD2. Subsequent qPCR analyses revealed a sig-
niﬁcant reduction of Gasp-2 expression in both cell lines, around
60% for KD1 and 65% for KD2 (Fig. 3A). Next, we assessed pro-
liferation and differentiation of both clones. KD1 and KD2 cell lines
present a reduced myoblast proliferation as the number of myo-
blasts is signiﬁcantly decreased after 48 h of culture (Fig. 3B).
Furthermore, Gasp-2 knockdown also leads to a decreased differ-
entiation (Fig. 3C). Indeed, the fusion index of both clones is de-
creased about 40% at 72 h and 60% at 96 h compared to the fusion
index of C2C12 and control cells (Fig. 3C). No variation in myotubes
size was observed in both clones. Myogenin expression is also
down-regulated by 50% at 72 h and 96 h of differentiation in both
Gasp-2 knockdown clones (Fig. 3D). Finally, we also observed a
global decrease of MyHC expression and a global decrease of p21
(a cyclin-dependent kinase inhibitor) in KD1 cell lines compared to
the control cells (Fig. 4A–C). Same results were observed in KD2
cell lines (data not shown). All these results correlated with an
impairment of differentiation when Gasp-2 is down-regulated.
Taken together, these data suggest that Gasp-2 plays an important
role during the normal progression of myogenesis, speciﬁcally
through regulation of both myoblast proliferation and
differentiation.
3.2. In silico analysis of potential glycosylation sites of murine
GASP-2
In silico analysis of GASP-2 with the NetNGlyc Server revealed
one consensus N-glycosylation site at asparagine N497. The Ne-
tOGlyc Server allowed us to highlight 6 serine or threonine, S170,
S171, T177, T178, T182, T206 with a mucin-type O-glycosylation
potential higher than the threshold. All were located between the
Follistatin/Kazal and the Igc2 domains except for T206 located in
the Igc2 domains (Fig. S1).
To examine the conservation of these glycosylation sites, an
alignment of GASP-2 primary sequences from 30 vertebrates was
performed and represented as a logo. The logo indicated that the
potential N-glycosylation site, N497, was highly conserved, corre-
lating with the NetNGlyc result. In addition, all the potential O-
glycosylation sites seemed conserved among vertebrates (Fig. S1).
3.3. In vitro validation of hGASP-2 state of glycosylation
We ﬁrst investigated the glycosylation state of the human re-
combinant protein GASP-2 by enzymatic digestions. Western
analyses after N-deglycosylation by PNGase F revealed that hGASP-
2 migrated faster than the untreated protein but the observed
molecular weight was still higher than the predicted one (Fig. 5).
Fig. 1. Enhancement of C2C12 cells proliferation by GASP-2 overexpression. (A) Proliferation analysis of C2C12 cells cultured for 72 h and treated in the absence (PBS) or
presence of 1 mg ml1 of hGASP-2 as measured by formazan assay. Each point corresponds to the mean 7 S.D. of three independent experiments. (B-D) Total proteins
extracted from C2C12 treated with PBS orhGASP-2 (1 mg ml1) were resolved by SDS-PAGE. Membranes were immunoblotted with speciﬁc anti-CDK2 and anti-p21 anti-
bodies. (E-F) Total proteins extracted from C2C12 treated with MSTN (250 ng ml1) and/or hGASP-2 (1 mg ml1) were resolved by SDS-PAGE. Membranes were im-
munoblotted with speciﬁc anti-pSMAD3 and anti-SMAD2/3 antibodies. (B-F) Nitrocellulose membranes were also probed with anti-GAPDH antibodies to show equal
loading. The graphs were obtained using Image J software to quantify CDK2, p21, pSMAD3 and SMAD2/3 signals normalized with GAPDH signals of three different
experiments.
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(O-Glycosidase, α-(2-3,6,8,9)-Neuraminidase, β-N-Acetylglucos-
aminidase,β-(1-4)-Galactosidase) to remove the mucin-type O-
glycans. This treatment allowed hGASP-2 to migrate at approxi-
mately 55 kDa, corresponding to its predicted molecular weight
without post-translational modiﬁcations. This result conﬁrmed
that GASP-2 is N- and O-glycosylated and suggested that these
glycosylations are the main post-translational modiﬁcations of
GASP-2.3.4. Fully deglycosylated GASP-2 protein can inhibit myostatin
To determine whether the N- and O-glycosylation is required
for GASP-2 to inhibit myostatin, we produced and puriﬁed the
murine GASP-2 in a prokaryotic system to obtain a recombinant
protein without glycosylation. We then tested the activity of the
deglycosylated GASP-2 on C2C12 myoblasts. C2C12 proliferation is
increased in the presence of 1 mg ml1 deglyco-mGASP-2 (Fig. 6).
This increase of the proliferation rate was comparable with the
Fig. 2. Enhancement of C2C12 cells differentiation by GASP-2 overexpression. (A) qPCR analysis of Gasp-2 expression in C2C12 transfected with pcDNA3.1-Gasp-2 (Cl1 and
Cl2) or pcDNA3.1-empty (pControl). Each histogram corresponds to the mean7S.D. of three independent experiments. The graph represents fold change normalized to Dffa
and β2m expression.(B) Quantiﬁcation of fusion index C2C12 myotubes transfected with pcDNA3.1-Gasp-2 (Cl1 and Cl2) or pcDNA3.1-empty (pControl) and cultured for 96 h
of differentiation. Each point corresponds to the mean 7 S.D. of three experiments. (C) qPCR analysis of Myogenin expression during 96 h of differentiation in C2C12
myotubes transfected with pcDNA3.1-Gasp-2 (Cl1 and Cl2) or pcDNA3.1-empty (pControl). Each point corresponds to the mean 7 S.D. of three independent experiments.
The graph represents fold change normalized to Dffa and β2m. Statistical signiﬁcance was determined using a t-test analysis. *: po0.05; **: po0.01; ***: p valueo0.005.
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mercial hGASP-2 (Fig. 6).4. Discussion
In this work, we investigated the function of GASP-2 during
myogenesis and the importance of glycosylation on its protein
activity. Although GASP-2 was shown to interact in vitro with
myostatin [8,9], no data are available concerning the effect of this
interaction in a muscular context. A recent study showed that
knock-out Gasp-1-/- or Gasp2-/- mice, present a muscular atrophy
from 8 months of age and defects in muscle regeneration [17],
strongly suggesting an involvement of GASP-2 in myostatin reg-
ulation during muscle development. To get a better understanding
on GASP-2 functions at cellular and molecular levels, we treated
C2C12 cells with either GASP-2 as recombinant proteins or viral
particles containing several speciﬁc shRNAs against Gasp-2. We
showed here for the ﬁrst time that GASP-2, like its paralogue
GASP-1, promotes the proliferation and the differentiation of
myoblasts by the inhibition of the myostatin canonical pathway
[14,18,19]. No signiﬁcant differences were observed on the devel-
opment of myoblasts treated with GASP-1 or GASP-2 (data not
shown). These data are consistent with the phenotypes described
in Gasp-1 and Gasp-2 knock-out mice, even if the atrophy is less
pronounced in Gasp-2-/-mice [17]. This could suggest that GASPs
are equally involved in muscle development and have a functionalredundancy. Therefore, it would be interesting to analyze Gasp-1
and Gasp-2 gene expression levels in Gasp2-/-and Gasp-1-/- mice
respectively. In addition, double knock-out Gasp1-/-; Gasp2-/- mice
analyses would conﬁrm the involvement of these genes during
muscle development. In addition to redundancy between GASP-1
and GASP-2, some studies have reported around myostatin and
GDF11 redundancy by characterizing double knock-out Mstn-/-;
Gdf11-/- [20–22]. These mice present only severe axial skeletal
defects but no abnormality of skeletal muscle as Gdf-11-/- single
mice [20]. All these data suggested no function of GDF-11 in
muscle development. Although GASP-2 can inhibit both myostatin
and GDF-11, the effects on myogenesis that we observed should be
the result of myostatin regulation [17].
We further investigated the structure/function relationship of
GASP-2 during its interaction with myostatin. Particularly we fo-
cused our study on how GASP-2 glycosylation may inﬂuence the
interaction between the two proteins and the inhibition function
of GASP-2. The two main forms of glycosylation found on secreted
glycoproteins are the N-glycans and the mucin-type O-glycans.
Thus, we ﬁrst identiﬁed by in silico analyses the potential sites
where GASP-2 could be glycosylated. We determined that GASP-2
sequence present a single consensus sequence for N-glycosylation
localized in the Netrin domain, that we have later found occupied,
and six potential sites of O-glycosylation between the Follistatin/
Kazal and the IgC2 domains. Although we are able to prove the
presence of mucin-type O-glycans on GASP-2, we cannot de-
termine their exact number and position on the protein. In the aim
Fig. 3. Inhibition of C2C12 cells proliferation and differentiation by Gasp-2 knockdown. (A) qPCR analysis of mGasp-2 transcriptional expression in C2C12 cells infected with
lentivirus containing either empty shRNA (pControl) or shRNAs (KD1 and KD2) designed to speciﬁcally target and repress mGasp-2. Each histogram corresponds to the mean
7 S.D. of three independent experiments. The graph represents fold change normalized to Dffa and β2m. (B) Proliferation analysis of C2C12 cells cultured for 48 h not
infected or infected with lentivirus containing either empty shRNA (pControl) or shRNAs (KD1 and KD2) as measured by formazan assay. Each histogram corresponds to the
mean 7 S.D. of three independent experiments. (C) Quantiﬁcation of fusion index C2C12 myotubes infected with lentivirus containing either empty shRNA (pControl) or
shRNAs (KD1 and KD2) and cultured for 96 h of differentiation. Each point corresponds to the mean 7 S.D. of three experiments. (D) qPCR analysis of Myogenin expression
during 96 h of differentiation in C2C12 myotubes infected with lentivirus containing either empty shRNA (pControl) or shRNAs (KD1 and KD2). Each point corresponds to the
mean 7 S.D. of three independent experiments. The graph represents fold change normalized to Dffa and β2m. Statistical signiﬁcance was determined using a t-test analysis.
*: po0.05; **: po0.01; ***: po0.005.
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protein, we decided to produce mGASP-2 in a bacterial system.
C2C12 cells treated with deglyco-mGASP-2 did not present any
difference in their proliferation compared to cells treated with the
fully glycosylated hGASP-2. Nevertheless, we cannot exclude dif-
ferences in effectiveness with lower protein concentration. Like its
paralogue GASP-1, our result seems to prove that glycosylation is
not necessary on GASP-2 inhibitor function of myostatin actions.
Furthermore, the N-glycosylation could play a role in GASP-2 se-
cretion like it was shown for GASP-1 [19].
We previously reported that the N-glycan site in the Netrin
domain and the localization of the O-glycans sites are particularly
well conserved among mammals and between the two GASPs [5].
This high degree of conservation tends to indicate that these gly-
cans may play a role in other GASPs biological activities. As the
Netrin domain is known to interact with myostatin propeptide, the
N-glycosylation could modulate this interaction and help to
maintain myostatin in its latent complex form [6,10,23]. An in-
teraction test between the propeptide and the deglycosylated form
of GASP-2 will help to conﬁrm this hypothesis. It is well known
that O-glycans participate in the tridimensional structure [24]. In a
muscular context, their presence near the Follistatin/Kazal domain
may modulate the interaction with myostatin. Moreover, mucin-
type O-glycans were shown to protect proteins against proteolysis
[25]. During the interaction between GASPs and myostatin latentcomplex, their presence may prevent the propeptide degradation
and myostatin activation by hiding the cleavage site of the pro-
peptide from BMP-1/Tolloid family [26].
In addition to skeletal muscle, GASPs proteins present a wide
tissular expression pattern including kidney, ovary, testis, lung,
brain and are highly expressed in pancreas [4]. This latter organ
secrets large amount of digestive enzymes, such as trypsin, elas-
tase and chymotrypsin, known to be targets of protease inhibitors.
While only an antitrypsin activity of GASPs second Kunitz domain
has been described, 3D structure studies indicate that trypsin is
not the prime target of this domain [8,23,27], suggesting that most
relevant proteases remain to be identiﬁed. The role of GASP gly-
cosylation in this context should be explored.5. Conclusions
This structure-function relationship study of GASP-2 demon-
strates for the ﬁrst time its effect on the myostatin signaling
pathway during myogenesis. We also show that the lack of any
type of glycosylation does not seem to affect its inhibitory role of
myostatin actions. Nevertheless, these glycans structures could be
involved in other GASP-2 biological activities and need to be in-
vestigated in the future.
Fig. 4. Expression of MyHC and p21 in Gasp-2 knockdown cells. (A) Immunoblot analysis of MyHC and p21 from 0 h to 96 h of differentiation C2C12 myotubes infected with
lentivirus containing either empty shRNA (pControl) or shRNAs (KD1). (B-C) Nitrocellulose membranes were also probed with anti-GAPDH antibodies to show equal loading.
The graphs were obtained using Image J software to quantify MyHC and p21 normalized with GAPDH signals of three different experiments. Statistical signiﬁcance was
determined using a t-test analysis. *:po0.05; **: po0.01; ***: po0.005.
Fig. 5. Characterization of the glycosylation state of hGASP-2 protein. Glycosylated
(lane 1), N-deglycosylated (lane 3); N- and O-deglycosylated hGASP-2 protein were
detected by Western blot with speciﬁc anti-GASP-2 antibody (1:1000).
Fig. 6. Effects of deglycosylated mGASP-2 on C2C12 myoblast proliferation. Pro-
liferation analysis of C2C12 cells in the absence (PBS) or presence of the murine
deglycosylated GASP-2 protein (deglyco-mGASP-2, produced in E.coli) cultured for
72 h as measured by formazan assay. Each point corresponds to the mean 7 S.D. of
three independent experiments. Statistical signiﬁcance was determined using a t-
test analysis. **:po0.01; ***: po0.005.
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